Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

Core Insights - Jasper Therapeutics reported positive clinical data for briquilimab, an antibody therapy targeting KIT for chronic spontaneous urticaria (CSU) and other mast cell-driven diseases [2][3][11] BEACON Study Results - In the BEACON study, 67% of additional patients (n=6) achieved a complete response at 12 weeks, with a mean UAS7 reduction of 31 points [1][5] - 83% of participants in the 240mg/180mg Q8W cohort achieved a complete response by week 3 [2][5] - The study is a randomized, double-blind, placebo-controlled Phase 1b/2a trial focusing on safety, tolerability, and clinical activity [4] Open Label Extension Study Results - In the open-label extension study, 58% of CSU participants (n=36) achieved a complete response at 12 weeks, and 75% achieved either a complete response or well-controlled disease [9][10] - The study included a median follow-up duration of 205 days for 63 patients, with no dose-limiting toxicities observed [10] Safety Profile - Briquilimab was well-tolerated in both studies, with low-frequency, low-grade adverse events related to KIT blockade, none resulting in discontinuations [6][10] Future Plans - The data from the BEACON and open-label extension studies are deemed sufficient to support dose selection for a planned Phase 2b study in CSU, expected to commence in the second half of 2026 [11]